Difference between revisions of "Section 1: Introduction (from DOI: 10.1084/jem.20200653) (Q11178)"
Jump to navigation
Jump to search
(Created claim: Has Sectioning (P146): Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653) (Q11181), #quickstatements; #temporary_batch_1593027050476) |
(Created claim: Section or subsection level in publication (P148): Main section in publication (Q7807), #quickstatements; #temporary_batch_1593027137586) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / Has Sectioning | |||
| + | |||
| Property / Has Sectioning: References (from DOI: 10.1084/jem.20200653) / rank | |||
| + | Normal rank | ||
| Property / IMRaD(C) Section | |||
| + | |||
| Property / IMRaD(C) Section: Introduction / rank | |||
| + | Normal rank | ||
| Property / Section or subsection level in publication | |||
| + | |||
| Property / Section or subsection level in publication: Main section in publication / rank | |||
| + | Normal rank | ||
Latest revision as of 19:32, 24 June 2020
Publication: "COVID-19 and emerging viral infections: The case for interferon lambda"published as J. Exp. Med.; 2020 05 04 ; 217 (5); DOI: 10.1084/jem.20200653
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 1: Introduction (from DOI: 10.1084/jem.20200653)
|
Publication: "COVID-19 and emerging viral infections: The case for interferon lambda"published as J. Exp. Med.; 2020 05 04 ; 217 (5); DOI: 10.1084/jem.20200653
|
Statements
0 references
